Therapies to treat rare and undiagnosed diseases are in high demand in a favorable regulatory environment. Thus, it is critically important to optimize the discovery and development of such therapies by creating – and following – the most efficient path to an investigational new drug (IND) filing. How do we do just that? In-depth scientific investigation, combined with efficiently planned study paradigms, are key to moving therapeutics along the drug development continuum.
Join us for a meeting of the minds on May 15th in Cambridge, MA as we host a one-day symposium to explore the challenges and success stories of rare disease drug discovery. Hailing from biotech, pharma, foundations, and academia, our diverse panel of speakers will share case studies and best practices. In addition to our scheduled presentations, the agenda will include panel discussions and networking breaks so bring your questions.
Don’t miss this opportunity to gain valuable insight on managing rare disease drug development through the preclinical pipeline.
Douglas MacDonald, PhD, Director Research Operations and Scientific Alliances, CHDI
Boston Cambridge Marriott Hotel
May 15th, 2017
Registration Opens at 8:00 AM
Scientific program – 8:50 AM to 5:30 PM
Followed by a networking reception
To learn more or to register: